Safety and effeficacy of drug-eluting beads chemoembolization for hepatocelluar carcinoma: comparison of DC Bead M1 versus Lipidol

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023798

Enrollment

Unknown

Registered

2019-06-12

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular cacinoma

Interventions

A:DC Bead M1

B:Lipidol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Child-Pugh A or B (score 7); ECOG PS 0-1; At least one untreated target lesion; BCLC A/B

Exclusion criteria

Exclusion criteria: Aged 70%; vascular invasion; extrahepatic metasis; predominant ascites; bilirubin > 3.0mg/dl; albumin 1.5; other malignancies within 5 years.

Design outcomes

Primary

Measure	Time frame
Objetive Resoponse Rate (mRECIST);Adverse Effect;	—

Countries

China

Contacts

Public ContactXiao Yudong

Intervention Department, The Second Xiangya Hospital of Central South University

546874341@qq.com+86 13637403027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026